Business Description
Hangzhou Tigermed Consulting Co Ltd
ISIN : CNE1000040M1
Share Class Description:
HKSE:03347: Class HCompare
Compare
Traded in other countries / regions
300347.China03347.Hong Kong5HZ1.GermanyHNGZY.USA IPO Date
2020-08-07Description
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.04 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | 1.45 | |||||
Interest Coverage | 37130.02 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 5.37 | |||||
Beneish M-Score | -2.26 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 28.8 | |||||
3-Year EBITDA Growth Rate | 3.7 | |||||
3-Year EPS without NRI Growth Rate | 24.3 | |||||
3-Year FCF Growth Rate | -2.8 | |||||
3-Year Book Growth Rate | 9.3 | |||||
Future 3-5Y EPS without NRI Growth Rate | 23.93 | |||||
Future 3-5Y Total Revenue Growth Rate | 15.25 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 16.62 | |||||
9-Day RSI | 30.9 | |||||
14-Day RSI | 38.56 | |||||
6-1 Month Momentum % | 11.79 | |||||
12-1 Month Momentum % | -26.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.61 | |||||
Quick Ratio | 2.61 | |||||
Cash Ratio | 1.67 | |||||
Days Inventory | 2.02 | |||||
Days Sales Outstanding | 59.74 | |||||
Days Payable | 16.72 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.2 | |||||
Dividend Payout Ratio | 0.32 | |||||
3-Year Dividend Growth Rate | 25.5 | |||||
Forward Dividend Yield % | 2.2 | |||||
5-Year Yield-on-Cost % | 8.44 | |||||
Shareholder Yield % | -0.71 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 38.14 | |||||
Operating Margin % | 23.08 | |||||
Net Margin % | 23.36 | |||||
FCF Margin % | 12.79 | |||||
ROE % | 8.14 | |||||
ROA % | 5.73 | |||||
ROIC % | 6.66 | |||||
ROC (Joel Greenblatt) % | 177.58 | |||||
ROCE % | 9.98 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 24.42 | |||||
Forward PE Ratio | 12.13 | |||||
PE Ratio without NRI | 27.16 | |||||
Shiller PE Ratio | 34.79 | |||||
Price-to-Owner-Earnings | 29.12 | |||||
PEG Ratio | 0.9 | |||||
PS Ratio | 5.71 | |||||
PB Ratio | 1.95 | |||||
Price-to-Tangible-Book | 2.29 | |||||
Price-to-Free-Cash-Flow | 44.62 | |||||
Price-to-Operating-Cash-Flow | 32.56 | |||||
EV-to-EBIT | 13.76 | |||||
EV-to-Forward-EBIT | 14.85 | |||||
EV-to-EBITDA | 13.76 | |||||
EV-to-Revenue | 4.8 | |||||
EV-to-Forward-Revenue | 4.22 | |||||
EV-to-FCF | 37.55 | |||||
Price-to-Projected-FCF | 1.5 | |||||
Price-to-DCF (Earnings Based) | 0.43 | |||||
Price-to-DCF (FCF Based) | 0.71 | |||||
Price-to-Median-PS-Value | 0.4 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.15 | |||||
Price-to-Graham-Number | 1.66 | |||||
Price-to-Net-Current-Asset-Value | 15.11 | |||||
Earnings Yield (Greenblatt) % | 7.27 | |||||
FCF Yield % | 2.4 | |||||
Forward Rate of Return (Yacktman) % | 21.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hangzhou Tigermed Consulting Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil HK$) | 7,865.317 | ||
EPS (TTM) (HK$) | 2.119 | ||
Beta | 1.29 | ||
Volatility % | 48.84 | ||
14-Day RSI | 38.56 | ||
14-Day ATR (HK$) | 1.515523 | ||
20-Day SMA (HK$) | 31.4625 | ||
12-1 Month Momentum % | -26.78 | ||
52-Week Range (HK$) | 22.1 - 50.5 | ||
Shares Outstanding (Mil) | 864.95 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Hangzhou Tigermed Consulting Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Hangzhou Tigermed Consulting Co Ltd Stock Events
Event | Date | Price(HK$) | ||
---|---|---|---|---|
No Event Data |
Hangzhou Tigermed Consulting Co Ltd Frequently Asked Questions
What is Hangzhou Tigermed Consulting Co Ltd(HKSE:03347)'s stock price today?
The current price of HKSE:03347 is HK$28.40. The 52 week high of HKSE:03347 is HK$50.50 and 52 week low is HK$22.10.
When is next earnings date of Hangzhou Tigermed Consulting Co Ltd(HKSE:03347)?
The next earnings date of Hangzhou Tigermed Consulting Co Ltd(HKSE:03347) is .
Does Hangzhou Tigermed Consulting Co Ltd(HKSE:03347) pay dividends? If so, how much?
The Dividend Yield %  of Hangzhou Tigermed Consulting Co Ltd(HKSE:03347) is 2.2% (As of Today), Highest Dividend Payout Ratio of Hangzhou Tigermed Consulting Co Ltd(HKSE:03347) was 0.64. The lowest was 0.21. And the median was 0.31. The  Forward Dividend Yield % of Hangzhou Tigermed Consulting Co Ltd(HKSE:03347) is 2.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |